신라젠, 7조 AML 항암제 시장 정조준… ‘전략·연구통’ 전면에

Shinlangen restructured its leadership with finance and R&D experts as it pursues the rapidly growing AML market, projected to reach 7 trillion won by 2029. The company's strong financial position with a 6% debt ratio and strategic focus on its BAL0891 pipeline present significant opportunities for technology licensing deals with global pharmaceutical firms.